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List!of!Abbreviations!!AAR! Area!at!risk!ACE! Angiotensin!converting!enzyme!ACS! Acute!coronary!syndrome!ANOVA! Analysis!of!variance!APC! Antigen!presenting!cell!ARB! Angiotensin!receptor!blocker!ATP! Adenosine!triphosphate!BCR! B!cell!receptor!BD! Becton!Dickinson!BMI! Body!mass!index!CABG! Coronary!artery!bypass!grafting!CAD! Coronary!artery!disease!CD! Cluster!of!differentiation!cDNA! Complementary!DNA!CI! Confidence!interval!CMP! Common!myeloid!precursor!CMR! Cardiac!magnetic!resonance!imaging!CMV! Cytomegalovirus!CS! Coronary!sinus!CT! Cycle!threshold!CTLs! Cytotoxic!T!lymphocytes!CV! Coefficient!of!variation!DAMP! Danger!associated!molecular!pattern!DAPT! Dual!antiplatelet!therapy!DC! Dendritic!cell!DMSO! Dimethyl!sulfoxide!DNA! Deoxyribonucleic!acid!ECG! Electrocardiogram!EDTA! Ethylenediaminetetraacetic!acid!
! xvii!
EDV! End!diastolic!volume!ELISA! EnzymeClinked!immunosorbent!assay!ELR! Glutamic!acidCleucineCarginine!ERK! ExtracellularCsignalCregulated!kinase!ESV! End!systolic!volume!FACS! Fluorescence!activated!cell!sorting!FBC! Full!blood!count!FITC! Fluorescein!isothiocyanate!FMO! Fluorescence!minus!one!FSC! Forward!scatter!g! Grams!GLP! GlucagonClikeCpeptide!GP! Glycoprotein!GRO! Growth!regulated!oncogene!H2O! Water!H2O2! Hydrogen!peroxide!HASTE! HalfCFourier!acquisition!single!shot!turbo!spin!echo!HCMV! Human!cytomegalovirus!HEV! High!endothelial!venules!hr! Hours!HR! Hazard!ratio!IFN! Interferon!IL! Interleukin!iNKT! Invariant!NKT!cell!IPC10! InterferonCγ!induced!proteinC10!IQR! Interquartile!range!I/R! Ischaemia/reperfusion!kg! Kilograms!KO! Knockout!LAD! Left!anterior!descending!artery!LBBB! Left!bundle!branch!block!
! xviii!
LGE! Late!gadolinium!enhancement!LPS! Lipopolysaccharide!LV! Left!ventricular/ventricular!LVEF! Left!ventricular!ejection!fraction!MACE! Major!adverse!cardiovascular!events!MBG! Myocardial!blush!grade!MCP! Monocyte!chemotactic!protein!MFI! Mean!fluorescence!intensity!MHC! Major!histocompatibility!complex!mg! Milligrams!MI! Myocardial!infarction!min! Minutes!MIP! Macrophage!inflammatory!protein!ml! Millilitres!MLP! Multilymphoid!progenitor!mmol! Millimoles!MPTP! Mitochondrial!permeability!transition!pore!MR! Magnetic!resonance!MRI! Magnetic!resonance!imaging!mRNA! Messenger!RNA!MVO! Microvascular!obstruction!ng! Nanograms!NHS! Newcastle!Health!Service!NK!cell! Natural!killer!cell!NKT!cell! Natural!killer!T!cell!NLR! Neutrophil!to!lymphocyte!ratio!NRES! National!Research!Ethics!Service!NSTEMI! NonCST!elevation!myocardial!infarction!O2! Oxygen!O2!C! Superoxide!anion!PBMC! Peripheral!blood!mononuclear!cell!
! xix!
PBS! Phosphate!buffered!saline!PCI! Percutaneous!coronary!intervention!PCR! Polymerase!Chain!Reaction!PE! Phycoerythrin!PerCP! Peridinin!chlorophyll!protein!complex!PKC! Protein!kinase!C!PPCI! Primary!percutaneous!coronary!intervention!PRR! PatternCrecognition!receptor!PVD! Peripheral!vascular!disease!RANTES! Regulated!upon!activation,!normal!TCcell!expressed!and!secreted!RCT! Randomised!controlled!trial!RISK! Reperfusion!Injury!Salvage!Kinase!RNA! Ribonucleic!acid!ROS! Reactive!oxygen!species!RTCPCR! Reverse!transcription!polymerase!chain!reaction!SD! Standard!deviation!SDF! Stromal!cellCderived!factor!SEM! Standard!error!of!the!mean!sFKN! Soluble!fractalkine!SI! Salvage!index!SSC! Side!scatter!SSFP! SteadyCstate!free!precession!STEMI! STCelevation!myocardial!infarction!STIR! Short!inversion!time!inversion!recovery!SV! Stroke!volume!TCE! T!cell!clonal!expansion!TCM! Central!memory!T!cell!TCR! T!cell!receptor!TE! Echo!time!TEM! Effector!memory!T!cells!TEMRA! Terminally!differentiated!effector!memory!T!cell!
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Chemokine& Synonyms& Receptors& Main&Target&Leucocytes& Notes&
CC&Chemokines&CCL2! <!Monocyte!chemotactic!protein!(MCP)<1! CCR2! Monocytes! <!Recruitment!of!inflammatory!monocytes!in!MI!(Liehn!et!al.,!2010).!CCL3! <!Macrophage!inflammatory!protein!(MIP)<1α! CCR1!CCR5! Monocytes!T!cells!! <!Upregulated!following!myocardial!I/R!(Dewald!et!al.,!2004).!<!May!have!a!role!in!neutrophil!recruitment!to!myocardium!and!ventricular!remodelling!in!mice!(Liehn!et!al.,!2008;!Liehn!et!al.,!2011a).!CCL4! <!MIP<1β! CCR5!CCR8! Monocytes,!T!cells,!Dendritic!cells!(DCs)! <!Upregulated!following!myocardial!I/R!(Dewald!et!al.,!2004).!<!Role!in!leucocyte!recruitment!in!MI!unknown!(Frangogiannis,!2007).!CCL5! <!Regulated!upon!activation,!normal!T<cell!expressed!and!secreted!(RANTES)!!
CCR1!CCR3!CCR5! Monocytes!T!cells!DCs! <!Administration!of!CCL5!antagonist!reduced!myocardial!monocyte!and!neutrophil!infiltration,!and!diminished!infarct!size!in!a!mouse!I/R!model!(Braunersreuther!et!al.,!2010).!
CCL7! <!MCP<3! CCR1!CCR2!CCR3! Monocytes!T!cells!(TH2>TH1)! <!Contributes!to!homing!of!mesenchymal!stem!cells!to!infarcted!myocardium!in!mice!(Schenk!et!al.,!2007).!<!Probable!role!for!B!cell!derived!CCL7!in!monocyte!recruitment!to!myocardium!post<MI!(Zouggari!et!al.,!2013).!






Chemokine! Synonyms! Receptors! Main&Target&
Leucocytes! Notes!
CXC&Chemokines! ! ! ! !CXCL1! <!Growth!regulated!oncogene!(GRO)<1!<!Keratinocyte!derived!chemokine!(KC)!
CXCR1!CXCR2! Neutrophils! <!Neutrophil!infiltration!in!a!rat!model!of!myocardial!I/R!(Chandrasekar!et!al.,!2001).!









































































































Model%1% Model%2%Sex!! Sex!!!Age!(per!10!years)! !Age!(per!10!years)!BMI! BMI!
Diabetes(mellitus! Diabetes(mellitus!
Family(history(of(CAD! Family(history(of(CAD!Hypertension! Hypertension!Current!or!ex!smoker! Current!or!ex!smoker!Previous!angina! Previous!angina!Previous!PCI! Previous!PCI!Previous!MI! Previous!MI!Previous!stroke/TIA! Previous!stroke/TIA!
Door(to(balloon(time((min)! Door(to(balloon(time((min)!
Total(ischemic(time((min)! Total(ischemic(time((min)!


















































































%Each!tube!was!analysed!on!a!BD!FACS!Canto!cytometer,!using!BD!FACSDiva!acquisition!software!(BD!Biosciences).!Each!sample!was!run!with!a!stop!gate!of!10000!T!cells,!to!ensure!adequate!numbers!for!representative!quantification!of!leucocyte!subsets.!!The!gating!of!the!leucocyte!populations!was!carried!out!as!follows:!! 1. An!initial!plot!of!forward!scatter!(FSC)!against!side!scatter!(SSC)!was!produced!to!ensure!a!normal!appearance!for!a!whole!blood!sample.!2. All!events!were!plotted!by!CD45HPerCP!against!side!scatter!(SSC),!and!a!gate!drawn!around!all!leucocytes.!
! 78!
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CD56- CD8+ T cells









Cell%Population% n%(of%duplicates)% Mean%CV%(%)%Leucocytes! 23! 1.4!Lymphocytes! 23! 1.5!T!cells! 23! 1.5!CD8+!T!cells! 23! 2.0!CD4+!T!cells! 23! 1.6!CD3K!Lymphocytes! 23! 1.7!Granulocytes! 23! 1.5!Monocytes! 23! 2.3!
%
Table%3.2:%Mean!CV!for!TruCount!assay!for!each!major!cell!population!quantified,!during!testing!of!duplicates!for!23!separate!blood!samples.!!!






3.3.6%T%Cell%Chemokine%Receptor%Expression%%!The!surface!expression!of!chemokine!receptors!in!T!cells!was!assessed!using!a!6Hcolour!flow!cytometric!assay.!A!cocktail!of!the!following!four!antibodies!was!added!to!aliquots!of!100μl!whole!blood,!while!one!sample!(FMO!CCR7)!was!also!prepared!without!the!antiHCCR7!antibody:!! H 20μl!antiHCD3HPE!(clone!UCHHT1,!BD!Biosciences,!#555333)!!H 5μl!antiHCD4HV400!(clone!RPAHT4,!BD!Biosciences,!#560768)!!H 20μl!antiHCD8HFITC!(clone!RPAHT8,!BD!Biosciences,!#555366)!H 5μl!antiHCCR7HBV421!(clone!G043H7,!Biolegend,!#353208,),!!!In!addition,!5μl!of!an!APCHlabelled!antibody!of!one!of!the!following!specificities!was!added:!!! H AntiHCCR1!(clone!5F10B29,!Biolegend,!#362908)!H AntiHCCR3!(clone!5E8,!Biolegend,!#310708)!H AntiHCCR9!(clone!L053E8,!Biolegend,!#358908)!
! 89!
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Age((years)( 62.8(±(13.3( 61.6(±(12.8( 74.6(±(12.6( 1377( <0.001'
Male(sex( 992((72.0)( 911((72.9)( 47((63.3)( 1377( 0.020'
BMI( 27.6(±(5.3( 27.7(±(5.2( 25.8(±(5.5( 1222( <0.001'
Diabetes(mellitus( 144((10.5)( 120((9.6)( 24((18.8)( 1375( 0.001'
Family(history(of(CAD( 553((44.6)( 519((45.7)( 34((32.7)( 1240( 0.011'
Hypertension( 553((40.2)( 492((39.4)( 61((47.7)( 1377( 0.069(
Hypercholesterolemia( 406((29.5)( 366((29.3)( 40((31.3)( 1377( 0.646(
Current(or(ex=smoker( 964((73.6)( 888((74.4)( 76((65.0)( 1310( 0.026'
( ( ( ( ( '
Previous(angina( 228((21.3)( 235((19.1)( 53((41.4)( 1352( <0.001'
Previous(PCI( 93((6.8)( 81((6.5)( 12((9.4)( 1374( 0.218(
Previous(MI( 194((14.4)( 157((12.8)( 37((31.1)( 1347( <0.001'
Previous(stroke(or(TIA( 67((4.9)( 57((4.6)( 10((7.8)( 1377( 0.126(
PVD( 46((4.9)( 39((3.1)( 7((5.5)( 1377( 0.189(
( ( ( ( ( (
Door(to(balloon(time((min)( 29.6(±(18.2( 29.3(±(18.4( 31.9(±(16.2( 1348( 0.009'
Total(ischemic(time((min)( 269.1(±(378( 266.8(±(371.2( 293.0(±(445.2( 1329( 0.011'
Cardiogenic(shock(pre=PPCI( 40((2.9)( 33((2.7)( 7((5.5)( 1367( 0.089(
Anterior(MI( 534((39.0)( 475((38.3)( 59((46.5)( 1368( 0.072(
Multivessel(PCI( 146((10.6)( 124((9.9)( 22((17.2)( 1377( 0.011'
TIMI(3(post=PCI( 1203((92.5)( 1102((93.3)( 101((84.2)( 1301( <0.001'
( ( ( ( ( (
Haemoglobin((g/l)( 139.5(±(16.5( 140.7(±(15.9( 128.1(±(17.9( 1374( <0.001'
Serum(cholesterol((mmol/l)( 5.0(±(1.3( 5.1(±(1.3( 4.4(±(1.3( 1283( <0.001'
Serum(creatinine((μmol/l)( 102.8(±(44.7( 99.0(±(30.4( 138.8(±(105.4( 1373( <0.001'
( ( ( ( ( (
Statin( 1238((89.9)( 1130((90.5)( 108((84.4)( 1377( 0.029'
ACE=inhibitor/ARB( 1191((86.5)( 1093((87.5)( 98((76.6)( 1377( 0.001'
Beta=blocker( 1158((84.1)( 1065((85.3)( 93((72.7)( 1377( <0.001'
Clopidogrel( 1252((90.9)( 1142((91.4)( 110((85.9)( 1377( 0.039'
Aspirin( 1256((91.2)( 1146((91.8)( 110((85.9)( 1377( 0.027'





















































































Age((years)( 69.0(±(13.3( 63.8(±(12.9( 60.9(±(12.9( 57.7(±(11.6( 1377( <0.001'
Male(sex( 247((72.2)( 244((72.4)( 245((68.8)( 256((74.9)( 1377( 0.361(
BMI( 26.8(±(5.4( 26.7(±(4.6( 28.3(±(5.6( 28.3(±(5.2( 1222( <0.001'
Diabetes(mellitus( 36((10.6)( 39((11.6)( 33((9.3)( 36((10.5)( 1375( 0.804(
Family(history(of(CAD( 112((38.4)( 149((49.7)( 130((39.9)( 162((50.3)( 1240( 0.002'
Hypertension( 153((44.7)( 152((45.1)( 129((36.2)( 119((34.8)( 1377( 0.005'
Hypercholesterolemia( 97((28.4)( 100((29.7)( 103((28.9)( 106((31.0)( 1377( 0.887(
Current(or(ex=smoker( 198((63.5)( 206((64.4)( 275((79.7)( 285((85.6)( 1310( <0.001'
Previous(angina( 92((27.5)( 68((20.2)( 60((17.3)( 68((20.1)( 1352( 0.009'
Previous(PCI( 33((9.7)( 25((7.4)( 19((5.3)( 16((4.7)( 1374( 0.039'
Previous(MI( 66((20.0)( 49((14.8)( 45((13.0)( 34((10.0)( 1347( 0.003'
Previous(stroke(or(TIA( 25((7.3)( 20((5.9)( 8((2.2)( 14((4.1)( 1377( 0.012'
PVD( 12((3.5)( 12((3.6)( 13((3.7)( 9((2.6)( 1377( 0.869(
( ( ( ( ( ( (
Door(to(balloon(time((min)( 32.5(±(20.2( 28.7(±(17.0( 28.6(±18.0( 28.5(±(17.1( 1348( 0.005'
Total(ischemic(time((min)( 289.6(±(399.5( 259.5(±(250.4( 251.5(±(410.3( 276.5(±(423.4( 1329( 0.001'
Cardiogenic(shock(Pre=PPCI( 18((5.3)( 10((3.0)( 4((1.1)( 8((2.4)( 1367( 0.012'
Anterior(MI( 161((47.4)( 118((35.1)( 136((38.6)( 119((35.0)( 1368( 0.002'
Multivessel(PCI( 51((14.9)( 35((10.4)( 31((8.7)( 29((8.5)( 1377( 0.021'
TIMI(3(post=PCI( 278((87.7)( 300((94.3)( 314((93.5)( 311((94.2)( 1301( 0.003'
( ( ( ( ( ( '
Haemoglobin((g/l)( 135.5(±(17.5( 137.9(±(17.5( 140.3(±(15.1( 144.2(±(14.7( 1374( <0.001'
Serum(cholesterol((mmol/l)( 4.6(±(1.3( 5.0(±(1.3( 5.1(±(1.2( 5.4(±(1.3( 1283( <0.001'
Serum(creatinine((μmol/l)( 113.6(±(68.6( 103.8(±(46.1( 98.2(±(23.7( 95.6(±(22.4( 1373( <0.001'
( ( ( ( ( ( '
Statin( 298((87.1)( 294((87.2)( 330((92.7)( 316((92.4)( 1377( 0.012'
ACE=inhibitor/ARB( 281((82.2)( 281((83.4)( 325((91.3)( 304((88.9)( 1377( 0.001'
Beta=blocker( 273((79.8)( 274((81.3)( 311((87.4)( 300((87.7)( 1377( 0.005'
Clopidogrel( 300((87.7)( 298((88.4)( 335((94.1)( 319((93.3)( 1377( 0.004'
Aspirin( 303((88.6)( 298((88.4)( 335((94.1)( 320((93.6)( 1377( 0.007'




























n( 342( 337( 356( 342( 1377( n/a(
Mortality(during(follow(up((%)( 64((18.7)( 32((9.5)( 23((6.5)( 9((2.6)( 128((9.3)( <0.001'!
Table%4.3:%Mortality!during!follow!up!for!STEMI!patients!discharged!alive,!according!to!minimum!lymphocyte!count!quartile.!Quartiles!compared!using!chi!squared!(χ2)!test.!! !




















































   Age (per 10 years)
3rd vs. 4th quartile
2nd vs. 4th quartile
1st vs. 4th quartile
Lymphocytes
Hazard ratio (95% CI)









confidence%interval)% p%value%Sex!! N/A! 0.633! N/A! 0.796!Age!(per!10!years)! 1.62!(1.31!–!1.99)! <0.001% 1.59!(1.29!–!1.97)! <0.001%BMI! N/A! 0.622! N/A! 0.986!
Diabetes(mellitus! 1.84!(1.02!–!3.33)! 0.045% N/A! 0.151!
Family(history(of(CAD! N/A! 0.675! N/A! 0.858!Hypertension! N/A! 0.406! N/A! 0.632!Current!or!ex!smoker! N/A! 0.821! N/A! 0.878!Previous!angina! 2.49!(1.55!–!4.00)! <0.001% 2.39!(1.48!–!3.85)! <0.001%Previous!PCI! N/A! 0.800! N/A! 0.976!Previous!MI! N/A! 0.685! N/A! 0.880!Previous!stroke/TIA! N/A! 0.808! N/A! 0.818!
Door(to(balloon(time((min)! N/A! 0.761! N/A! 0.775!
Total(ischemic(time((min)! N/A! 0.995! N/A! 0.788!
Cardiogenic(shock(Pre=PPCI! N/A! 0.119! N/A! 0.330!Anterior!MI! N/A! 0.499! N/A! 0.517!Haemoglobin!(per!10g/l)! N/A! 0.199! N/A! 0.102!Creatinine!(per!100μmol/l)! 1.55!(1.23!–!1.96)! <0.001% 1.53!(1.21!–!1.95)! <0.001%Statin! N/A! 0.341! N/A! 0.349!
ACE=inhibitor/ARB! N/A! 0.800! N/A! 0.989!
Beta=blocker! N/A! 0.697! N/A! 0.527!
Clopidogrel! N/A! 0.466! N/A! 0.461!
Aspirin! N/A! 0.525! N/A! 0.522!
GP(IIb/IIIa(inhibitor! 0.45!(0.27!–!0.76)! 0.003% 0.44!(0.26!–!0.74)! 0.002%! ! ! ! !
Lymphocyte%Quartiles% ! ! ! !Quartile!1!vs.!Quartile!4! 2.75!(1.16!–!6.55)! 0.022% Not!in!Model! N/A!Quartile!2!vs.!Quartile!4! 2.51!(1.06!–!5.94)! 0.036% Not!in!Model! N/A!Quartile!3!vs.!Quartile!4! 2.09!(0.85!–!5.13)!! 0.106! Not!in!Model! N/A!! ! ! ! !

































( STEMI'(n=59)' NSTEMI'(n=15)' p(value(
Age( 59.3(±(10.7( 61.1(±(11.8( 0.742(
Male(sex( 44((74.6)( 11((73.3)( 1.000(
BMI( 26.8(±(4.6( 30.9(±(6.0( 0.006'
Diabetes(mellitus( 6((10.2)( 0((0)( 0.337(
Family(history(of(CAD( 23((39.0)( 7((46.7)( 0.697(
Active(smoker( 31((52.5)( 4((26.7)( 0.089(
Hypertension( 19((32.2)( 10((66.7)( 0.020'
Anterior(MI( 28((47.5)( N/A( N/A(
Serum(cholesterol((mmol/l)( 5.3(±(1.1( 4.3(±(1.1( 0.036'
Serum(creatinine((μmol/l)( 80.2(±(17.0( 84.9(±(21.4( 0.472(
Peak(troponin(T((ng/l)( 4899(±(3385( 207(±(214( <0.001'
( ( ( (







Onset=to=procedure(time((days)( N/A( 5.01±(2.78( N/A(
Pre=PCI(flow((TIMI(0/1/2/3)( 55/4/0/0( 2/1/0/12( <0.001'
Post=PCI(flow((TIMI(0/1/2/3)( 0/0/0/59( 1/0/0/14( 0.203(
Vascular(access((radial/femoral)( 56/3( 13/2( 0.265(
( ( ( (
Pre>admission'Medication' ( ( (
Statin(therapy( 10((16.9)( 6((40.0)( 0.077(
Β=blocker( 2((3.4)( 3((20.0)( 0.054(
Aspirin( 5((8.5)( 2((13.3)( 0.624(
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infarct!groups!had!greater!LV!end!diastolic!and!systolic!volumes!(p=0.035!and!p=0.001!respectively),!lower!LVEF!(p=0.001)!and!more!MVO!(p<0.001)!than!smaller!infarcts.!!! ! MRI%(n=50)% No%MRI%(n=9)% p%value%Age! 58.5!±!10.1! 64!±!13.0! 0.164!Male!sex!! 41!(82.0)! 3!(33.3)! 0.006%BMI! 26.9!±!4.6! 26.3!±!4.2! 0.958!Diabetes!mellitus! 4!(8.0)! 2!(22.2)! 0.224!Family!history!of!CAD! 20!(40.0)! 3!(33.3)! 0.742!Active!smoker! 26!(52.0)! 5!(55.6)! 1.000!Hypertension! 16!(32.0)! 3!(33.3)! 1.000!Anterior!MI! 26!(52.0)! 2!(22.2)! 0.150!Serum!cholesterol!(mmol/l)! 5.2!±!1.0! 5.6!±!1.5! 0.681!Serum!creatinine!(μmol/l)! 81.6!±!16.9! 72.4!±!16.2! 0.194!Peak!troponin!T!(ng/l)! 5086!±!3435! 4515!±!3234! 0.627!DoorHtoHballoon!time!(minutes)! 27.2!±!14.9! 24.6!±!11.0! 0.834!OnsetHtoHreperfusion!time!(minutes)% 160.4!±!79.1! 187.9!±!94.6! 0.376!! ! ! !
PreKadmission%Medication! ! ! !Statin!therapy! 8!(16.0)! 2!(22.2)! 0.641!ΒHblocker! 1!(2.0)! 1!(11.1)! 0.284!Aspirin! 4!(8.0)! 1!(11.1)! 0.577!ACEHinhibitor/ARB% 5!(10.0)! 1!(11.1)! 1.000!! ! ! !





p%value%! None%(0g)% Low%(0.1K2.7g)% High%(>2.7g)%n! 19! 14! 17! n/a!Age! 57.5!±!7.3! 61.0!±!12.1! 57.5!±!11.3! 0.698%Male!sex!! 15!(78.9)! 12!(85.7)! 14!(82.4)! 0.882!BMI! 28.0!±!5.0! 25.0!±!4.0! 27.2!±!4.4! 0.087!Diabetes!mellitus! 0!(0)! 1!(7.1)! 3!(17.6)! 0.148!Family!history!of!CAD! 9!(47.4)! 3!(21.4)! 8!(47.1)! 0.455!Active!smoker! 12!(63.2)! 6!(42.9)! 8!(47.1)! 0.453!Hypertension! 8!(42.1)! 1!(7.1)! 7!(41.2)! 0.063!Anterior!MI! 6!(31.6)! 9!(64.3)! 11!(64.7)! 0.077!Serum!cholesterol!(mmol/l)! 5.2!±!1.0! 5.4!±!0.8! 5.2!±!1.1! 0.826!Serum!creatinine!(μmol/l)! 77.6!±!13.6! 79.4!±!15.4! 87.8!±!20.2! 0.244!Peak!troponin!T!(ng/l)! 2493!±!2197! 4213!±!1853! 8703!±!2318!! <0.001%DoorHtoHballoon!time!(minutes)! 29.8!±!18.2! 26.1!±!13.1! 25.1!±!12.1! 0.738!OnsetHtoHreperfusion!time!(minutes)! 173.2!±!85.6! 158.5!±!66.8! 147.6!±!83.1! 0.455!
% ! ! ! !
PreKadmission%Medication! ! ! ! !Statin!therapy! 4!(21.1)! 1!(7.1)! 3!(17.6)! 0.545!ΒHblocker! 1!(5.3)! 0!(0)! 0!(0)! 0.435!Aspirin! 1!(5.3)! 0!(0)! 3!(17.6)! 0.169!ACEHinhibitor/ARB% 2!(10.5)! 0!(0)! 3!(17.6)! 0.264!
% ! ! ! !
Treatment%During%PPCI! ! ! ! !Aspirin! 19!(100)! 14!(100)! 17!(100)! n/a!Additional!antiplatelet!(prasugrel/clopidogrel/ticagrelor)! 17/2/0! 12/1/1! 15/0/2! 0.430!Heparin! 18!(94.7)! 14!(100)! 17!(100)! 0.435!Abciximab! 9!(47.4)! 3!(21.4)! 10!(58.8)! 0.105!Tirofiban! 5!(26.3)! 5!(35.7)! 4!(23.5)! 0.738!Bivalirudin! 2!(10.5)! 5!(35.7)! 3!(17.6)! 0.193!Aspiration!catheter! 16!(84.2)! 11!(78.6)! 14!(82.4)! 0.916!! ! ! ! !





p%value%! Small%(<13.3%)% Medium%(13.3K23.8)% Large%(>23.8%)%n! 16! 18! 16! n/a!Age! 60.1!±!9.6! 57.6!±!10.1! 57.8!±!11.1! 0.783!Male!sex!! 12!(75.0)! 15!(83.3)! 14!(87.5)! 0.644!BMI! 27.5!±!4.8! 27.3!±!5.4! 25.9!±!3.4!! 0.687!Diabetes!mellitus! 0!(0.0)! 2!(11.1)! 2!(12.5)! 0.356!Family!history!of!CAD! 6!(37.5)! 8!(44.4)! 6!(37.5)! !0.857!Active!smoker! 9!(56.3)! 9!(50.0)! 8!(50.0)! 0.918!Hypertension! 7!(43.8)! 5!(27.8)! 4!(25.0)! 0.467!Anterior!MI! 4!(25.0)! 9!(50.0)! !13!(81.3)! 0.006%Serum!cholesterol!(mmol/l)! 5.2!±!1.1! 5.3!±!1.0! 5.3!±!0.8! 0.929!Serum!creatinine!(μmol/l)! 76.6!±!13.2! 84.1!±!20.7! 83.8!±!15.3! 0.369!Peak!troponin!T!(ng/l)! 2027!±!1936! 5112!±!2335! 8115!±!2976! <0.001%DoorHtoHballoon!time!(minutes)! 26.9!±!13.2! 29.4!±!18.4! 24.9!±!12.2! 0.652!OnsetHtoHreperfusion!time!(minutes)! 170.1!±!47.1! 175.2!±!104.5! 133.9!±!68.7! 0.103!
% ! ! ! !
PreKadmission%Medication! ! ! ! !Statin!therapy! 3!(18.8)! 2!(11.1)! 3!(18.8)! 0.779!ΒHblocker! 1!(6.3)! 0!(0.0)! 0!(0.0)! 0.338!Aspirin! 1!(6.3)! 1!(5.6)! 2!(12.5)! 0.721!ACEHinhibitor/ARB% 1!(6.3)! 2!(11.1)! 2!(12.5)! 0.825!
% ! ! ! !
Treatment%During%PPCI! ! ! ! !Aspirin! 16!(100)! 18!(100)! 16!(100)! n/a!Additional!antiplatelet!(prasugrel/clopidogrel/ticagrelor)! 12/3/0! 13/2/3! 14/1/1! 0.359!Heparin! 15!(93.8)! 18!(100)! 16!(100)! 0.338!Abciximab! 7!(43.8)! 7!(38.9)! 8!(50.0)! 0.809!Tirofiban! 5!(31.3)! 4!(22.2)! 5!(31.3)! 0.792!Bivalirudin! 3!(18.8)! 5!(27.8)! 2!(12.5)! 0.533!Aspiration!catheter! 11!(68.8)! 15!(83.3)! 15!(93.8)! 0.181!! ! ! ! !





















) r = -0.06
p = 0.70





































































) r = 0.76
p < 0.001
















































) r = 0.47
p = 0.020
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p%value%CCR2! 0.264! 0.487!CCR4! 0.187! 0.568!CCR5! 0.709! 0.158!CXCR1! 0.948! 0.026%CXCR2! 0.954! 0.023%CXCR3! 0.209! 0.543!CXCR4! 0.074! 0.729!CXCR6! 0.928! 0.037%CX3CR1! 0.987! 0.006%
%
Table%7.1:%Correlations!between!T!cell!subset!expression!of!chemokine!receptors!in!STEMI!patients!(n=5)!and!the!observed!drop!in!respective!subsets!in!the!full!STEMI!group!(preHreperfusion!to!90!minutes)!(n=59).%Data!for!all!analysed!chemokine!receptors!shown,!including!those!with!low!expression!and/or!not!known!to!be!significantly!involved!in!T!cell!trafficking.!Correlation!as!determined!by!linear!regression!and!Pearson!correlation!coefficient.!!! !













CCR2 vs. Δ0-90 min
r2=0.26
p=0.49
CCR7+ CD4 T cells
CCR7- CD4 T cells-
CCR7+ CD8 T cells
CCR7- CD8 T cells












CCR4 vs. Δ0-90 min
r2=0.19
p=0.57
CCR7+ CD4 T cells
CCR7- CD4 T cells-
CCR7+ CD8 T cells
CCR7- CD8 T cells














CCR5 vs. Δ0-90 min
r2=0.71
p=0.16
CCR7+ CD4 T cells
CCR7- CD4 T cells-
CCR7+ CD8 T cells
CCR7- CD8 T cells














CXCR3 vs. Δ0-90 min
r2=0.21
p=0.54
CCR7+ CD4 T cells
CCR7- CD4 T cells-
CCR7+ CD8 T cells
CCR7- CD8 T cells















CX3CR1 vs. Δ0-90 min
CCR7+ CD4 T cells
CCR7- CD4 T cells-
CCR7+ CD8 T cells



















CXCR4 vs. Δ0-90 min
r2=0.07
p=0.73
CCR7+ CD4 T cellsCCR7- CD4 T cells-
CCR7+ CD8 T cells

























































































































































































































































































































































Negative% Positive%n! 26! 33! n/a!Age! 55.3!±!10.2! 62.5!±!10.1! 0.011%Male!sex! 23!(88.5)! 21!(63.6)! 0.038%BMI! 27.5!±!4.7! 26.2!±!4.4! 0.202!Diabetes!mellitus! 1!(3.8)! 5!(15.2)! 0.215!Family!history!of!CAD! 8!(30.8)! 15!(45.5)! 0.177!Active!smoker! 14!(53.8)! 17!(51.5)! 1.000!Hypertension! 6!(23.1)! 13!(39.4)! 0.263!Anterior!MI! 14!(53.8)! 14!(42.4)!! 0.438!Serum!cholesterol!(mmol/l)! 5.3!±!1.0! 5.3!±!1.1! 0.630!Serum!creatinine!(μmol/l)! 84.0!±!19.6! 77.2!±!14.2! 0.181!Peak!troponin!T!(ng/l)! 4937!±!3627! 5047!±!3238! 0.867!! ! ! !
Procedural%Characteristics% ! ! !DoorHtoHballoon!time!(minutes)! 24.9!±!12.9! 28.4!±!15.4! 0.293!OnsetHtoHreperfusion!time!(minutes)! 152.3!±!80.7! 174.2!±!81.8! 0.192!PreHPCI!flow!(TIMI!0/1/2/3)! 25/1/0/0! 30/3/0/0! 0.623!PostHPCI!flow!(TIMI!0/1/2/3)! 0/0/0/26! 0/0/0/33! n/a!Vascular!access!(radial/femoral)! 25/1! 31/2! 1.000!! ! ! !
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